Literature DB >> 25386293

Hyperimmunoglobulin E syndrome in two siblings.

Abdulmohti Hawilo1, Inès Zaraa1, Sondes Trojjet1, Hella Zribi1, Rym Cheikh Rouhou1, Dalenda El Euch1, Mourad Mokni1, Amel Ben Osman1.   

Abstract

Hyperimmunoglobulin E recurrent infection syndrome (HIES) is characterized by recurrent skin and lung infections, eczema, elevated serum immunoglobulin E (IgE) levels (>2000 IU/mL), various connective tissue, skeletal, and vascular abnormalities.(1) We describe herein two brothers with HIES and documented the complications and management of such involvement.

Entities:  

Keywords:  atopic dermatitis; hyper-IgE syndrome; infection.; primary immunodeficiency

Year:  2011        PMID: 25386293      PMCID: PMC4211509          DOI: 10.4081/dr.2011.e41

Source DB:  PubMed          Journal:  Dermatol Reports        ISSN: 2036-7392


Case Report

A 4-year-old boy from a consanguineous marriage presented with a history of persistent eczematous rash since the age of weeks. No family history of asthma or atopic dermatitis was noted. Physical examination revealed a coarse facial appearance and growth retardation for his age (Figure 1A). There were eczematous patches, plaques and cold abscesses on extremities and scalp (Figure 1B). Pruritic dermatitis was noted in a distribution atypical for true atopic dermatitis (Figure 1C). Cultures of the abscess yielded Staphylococcus aureus. His serum IgE level was 3000IU/mL (normal 0-29.2 IU/mL); other immunoglobulin levels were normal. A parent's serum IgE level was markedly elevated. Based on the combination of chronic dermatitis resembling atopic dermatitis, relapsing severe bacterial infections of skin and increased IgE levels, the diagnosis of HIES was confirmed. He was successfully treated with topical corticosteroids, oral oxacillin and low-dose fluconazole. During the succeeding 23 years, he was hospitalized more times (exacerbation of dermatitis, skin and mucosal infections, pruritis) and treated by local and systemic corticosteroids (0.5 mg/kg prednisone), emollients, antibiotics, and antihistamines.
Figure 1

A) A coarse facial appearance with eczematous lesions in a boy with hyperimmunoglobulin E syndrome. B) Folliculitis of the scalp with scaring patches. C) Eczematous skin lesions with excoriations, papules and scaling.

A) A coarse facial appearance with eczematous lesions in a boy with hyperimmunoglobulin E syndrome. B) Folliculitis of the scalp with scaring patches. C) Eczematous skin lesions with excoriations, papules and scaling. His brother (2-year-old boy) presented with a history of recurrent dermatitis and furunculosis since 1 month of age. He was often afflicted with recurrent skin infections, pneumonia, and bronchitis. Cultures for skin abscesses and oral mucosa were positive (S. aureus and C. Albicans). Chemotactic defect in peripheral blood neutrophils was observed. The level of serum IgE was markedly elevated (10000 IU/mL), and anti-S.aureus specific IgE was found. At 5 years of age, he developed typical juvenile dermatomyositis (Figure 2) and treated by oral prednisone (2 mg/kg/day). He died at 11 year of age of septic shock infection. Our patients concerned the first two Tunisian cases of HIES, a rare primary immunodeficiency syndrome; less than 250 cases were documented in the literature.[1] The primary host defense defect is impaired phagocytosis.[2,3] As observed in patient 2, serum from HIE patients can inhibit the neutrophilic chemotaxis of healthy patients when added to their serum. Clinical manifestations often start with eczematous or atopic dermatitis-like eruptions within the first days of life as in our patients. Recurrent pyogenic pneumonias usually start in early childhood. Other manifestations described since then include: coarse faces as in our first observation, skeletal abnormalities, and vascular abnormalities[4] (Table 1). The mode of inheritance appears to be autosomal dominant with incomplete penetrance; the gene has been linked to chromosome 4q.[5] Recently, dominant-negative mutations in the signal transducer and activator of transcription 3 (STAT3) gene were identified.[3] In this report, the genetic study was not performed. As reported in patient 2, the association of dermatomyositis with HIES is extremely rare (only 2 reports) and may not have been coincidental.6 At present, no established protocol exists for the treatment of HIES. Prevention of infection is the cornerstone of therapy. Bone marrow transplantation has been performed but is likely not fully corrective.[7] Long-term chemoprophylaxis (oral penicillin's and low-dose fluconazole) in patient 1 improved dramatically the course of the disease.
Figure 2

Dermatomyosis in a boy with hyper-immunoglobulin E syndrome.

Table 1

Clinical manifestations and Immunologic features of HIES.

Clinical manifestations
Cutaneous manifestations
 Newborn vesicopustular eosinophilic eruption
 Atopic eczema-like dermatitis Infected dermatitis and folliculitis - Staphylococcus aureus Cold abscesses
 Chronic candidiasis Generalized coarsening of the skin
Pulmonary manifestations
 Parenchymal lung disease
 Pneumatoceles
 Recurrent pneumonias-S aureus and Haemophilus influenzae
 Pulmonary abscesses-Pseudomonas aeruginosa, Aspergillus fumigatus
Musculoskeletal findings
 Retained primary teeth
 Scoliosis
 Osteopenia/osteoporosis
 Frequent fracture of long bones
 Midline anomalies-cleft palate, cleft tongue, high palate, hemivertebrae
Characteristic facies
 Facial asymmetry with hemihypertrophy
 Prominent forehead
 Broadened nasal bridge and deep-set eyes
 Increased alar and outer canthal distance
Rare Systemic infections (Nocardiosis, candidiasis, cryptococcosis, histoplasmosis, sporotrichinosis, herpesvirus, pneumocystis carinii), miscellaneous
 Bowel perforation, giant chalazion, genu valgum, joint deformities, spinal anomalies, lymphoma, connective tissue disease

GM-CSF, Granulocyte-monocyte colony-stimulating factor; IFN, Interferon; IL, interleukin; TGF, transforming growth factor.

Dermatomyosis in a boy with hyper-immunoglobulin E syndrome. GM-CSF, Granulocyte-monocyte colony-stimulating factor; IFN, Interferon; IL, interleukin; TGF, transforming growth factor.
  6 in total

Review 1.  Hyperimmunoglobulin E syndrome: two cases and a review of the literature.

Authors:  Christine A DeWitt; Amanda B Bishop; Lucinda S Buescher; Stephen P Stone
Journal:  J Am Acad Dermatol       Date:  2006-05       Impact factor: 11.527

2.  Genetic linkage of hyper-IgE syndrome to chromosome 4.

Authors:  B Grimbacher; A A Schäffer; S M Holland; J Davis; J I Gallin; H L Malech; T P Atkinson; B H Belohradsky; R H Buckley; F Cossu; T Español; B Z Garty; N Matamoros; L A Myers; R P Nelson; H D Ochs; E D Renner; N Wellinghausen; J M Puck
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

3.  Hyperimmunoglobulin E syndrome with juvenile dermatomyositis and calcinosis.

Authors:  Bedangshu Saikia; Himanshu Aneja; Jyoti Jain; Jacob M Puliyel
Journal:  Clin Rheumatol       Date:  2010-04-08       Impact factor: 2.980

4.  Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder.

Authors:  B Grimbacher; S M Holland; J I Gallin; F Greenberg; S C Hill; H L Malech; J A Miller; A C O'Connell; J M Puck
Journal:  N Engl J Med       Date:  1999-03-04       Impact factor: 91.245

Review 5.  Hyper-IgE syndrome.

Authors:  Yoshiyuki Minegishi
Journal:  Curr Opin Immunol       Date:  2009-08-28       Impact factor: 7.486

6.  Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.

Authors:  Ellen D Renner; Stacey Rylaarsdam; Stephanie Anover-Sombke; Anita L Rack; Janine Reichenbach; John C Carey; Qili Zhu; Annette F Jansson; Julia Barboza; Lena F Schimke; Mark F Leppert; Melissa M Getz; Reinhard A Seger; Harry R Hill; Bernd H Belohradsky; Troy R Torgerson; Hans D Ochs
Journal:  J Allergy Clin Immunol       Date:  2008-07       Impact factor: 10.793

  6 in total
  1 in total

1.  Hyperimmunoglobulin E syndrome (Job syndrome): chest CT findings.

Authors:  Pablo Rydz Pinheiro Santana; Augusto Kreling Medeiros; Cinthia Callegari Barbisan; Antônio Carlos Portugal Gomes; Edson Marchiori
Journal:  J Bras Pneumol       Date:  2018 Jul-Aug       Impact factor: 2.624

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.